- Home
- PLBY vs CALC Comparison
PLBY vs CALC Comparison
Compare PLBY & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBY
- CALC
- Stock Information
- Founded
- PLBY 1953
- CALC 2011
- Country
- PLBY United States
- CALC United States
- Employees
- PLBY N/A
- CALC N/A
- Industry
- PLBY Recreational Games/Products/Toys
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PLBY Consumer Discretionary
- CALC Health Care
- Exchange
- PLBY Nasdaq
- CALC Nasdaq
- Market Cap
- PLBY 138.1M
- CALC 22.9M
- IPO Year
- PLBY N/A
- CALC N/A
- Fundamental
- Price
- PLBY $1.63
- CALC $1.61
- Analyst Decision
- PLBY Hold
- CALC Strong Buy
- Analyst Count
- PLBY 1
- CALC 3
- Target Price
- PLBY $0.70
- CALC $16.33
- AVG Volume (30 Days)
- PLBY 280.1K
- CALC 30.2K
- Earning Date
- PLBY 08-07-2025
- CALC 08-11-2025
- Dividend Yield
- PLBY N/A
- CALC N/A
- EPS Growth
- PLBY N/A
- CALC N/A
- EPS
- PLBY N/A
- CALC N/A
- Revenue
- PLBY $116,691,000.00
- CALC N/A
- Revenue This Year
- PLBY $3.96
- CALC N/A
- Revenue Next Year
- PLBY $1.75
- CALC N/A
- P/E Ratio
- PLBY N/A
- CALC N/A
- Revenue Growth
- PLBY N/A
- CALC N/A
- 52 Week Low
- PLBY $0.52
- CALC $1.42
- 52 Week High
- PLBY $2.44
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- PLBY 60.48
- CALC 47.03
- Support Level
- PLBY $1.54
- CALC $1.42
- Resistance Level
- PLBY $1.73
- CALC $1.85
- Average True Range (ATR)
- PLBY 0.09
- CALC 0.15
- MACD
- PLBY 0.00
- CALC -0.00
- Stochastic Oscillator
- PLBY 69.91
- CALC 44.19
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.